Pharmacological action
A combined contraceptive drug containing estrogen and gestagen.
The contraceptive effect of the drug, like other combined oral contraceptives, is based primarily on the ability to suppress ovulation and increase the secretion of cervical mucus.
Desogestrel suppresses the synthesis of gonadotropic hormones, mainly LH, thus preventing follicle maturation (blocks ovulation).
Ethinyl estradiol is a synthetic analogue of the follicular hormone estradiol, together with the corpus luteum hormone it regulates the menstrual cycle.
Along with the above-mentioned central and peripheral mechanisms that prevent the maturation of a fertilizable egg, the contraceptive effect is due to an increase in the viscosity of the mucus in the cervix, which makes it difficult for sperm to enter the uterine cavity.
In addition to its contraceptive properties, the drug has a number of effects that can be taken into account when choosing a contraceptive method. Menstrual-like reactions become more regular, are less painful and are accompanied by less severe bleeding. The latter circumstance leads to a decrease in the frequency of concomitant iron deficiency anemia.
Taking contraceptive drugs with a high content of ethinyl estradiol (50 mcg) reduces the risk of developing ovarian and endometrial cancer. There is no data confirming this pharmacological effect for contraceptive drugs with a lower content of ethinyl estradiol. Indications for the active ingredients of Marvelon®
Contraception
Contraindications for use
Current or history of venous or arterial thrombosis/thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke); precursors of thrombosis (including transient ischemic attack, angina); identified predisposition to venous or arterial thrombosis, including resistance to activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (antibodies to cardiolipin, lupus anticoagulant); history of migraine with focal neurological symptoms; diabetes mellitus with diabetic angiopathy; The presence of multiple factors or a high degree of expression of one of the risk factors for the development of venous or arterial thrombosis, thromboembolism; Uncontrolled arterial hypertension (BP 160/100 mmHg and higher); Pancreatitis (including history), accompanied by severe hypertriglyceridemia; Severe dyslipoproteinemia; Liver failure, acute or severe liver disease (before normalization of liver function tests), including history; Liver tumors (benign and malignant), including history; Hormone-dependent malignant neoplasms of the genitals or mammary glands (including suspected); Vaginal bleeding of unknown etiology; Pregnancy (including suspected); Lactation period (breastfeeding); Smoking at the age of over 35 years (more than 15 cigarettes/day); lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome; adolescent girls under 18 years of age (there is no data on the efficacy and safety of the drug); hypersensitivity to the components of the drug.
If any of the above diseases (conditions) occur while using the drug (as well as other COCs), you should immediately stop taking the drug.
Warning: always consult a doctor before using medications.
